{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-10",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "submissions": [
        {
          "submission_type": "ORIG",
          "submission_number": "1",
          "submission_status": "AP",
          "submission_status_date": "20201125",
          "review_priority": "PRIORITY",
          "submission_class_code": "TYPE 1",
          "submission_class_code_description": "Type 1 - New Molecular Entity",
          "submission_property_type": [
            {
              "code": "Orphan"
            }
          ],
          "application_docs": [
            {
              "id": "65350",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf",
              "date": "20201125",
              "type": "Label"
            },
            {
              "id": "65359",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761171Orig1s000ltr.pdf",
              "date": "20201127",
              "type": "Letter"
            },
            {
              "id": "65696",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761171Orig1s000TOC.html",
              "date": "20201222",
              "type": "Review"
            }
          ]
        },
        {
          "submission_type": "SUPPL",
          "submission_number": "13",
          "submission_status": "AP",
          "submission_status_date": "20250827",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "submission_property_type": [
            {
              "code": "Orphan"
            }
          ],
          "application_docs": [
            {
              "id": "83216",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761171s013lbl.pdf",
              "date": "20250828",
              "type": "Label"
            },
            {
              "id": "83234",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/761171Orig1s013ltr.pdf",
              "date": "20250829",
              "type": "Letter"
            }
          ]
        },
        {
          "submission_type": "SUPPL",
          "submission_number": "8",
          "submission_status": "AP",
          "submission_status_date": "20240320",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "submission_property_type": [
            {
              "code": "Orphan"
            }
          ],
          "application_docs": [
            {
              "id": "77898",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761171Orig1s008ltr.pdf",
              "date": "20240321",
              "type": "Letter"
            },
            {
              "id": "77910",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761171s008lbl.pdf",
              "date": "20240321",
              "type": "Label"
            }
          ]
        }
      ],
      "application_number": "BLA761171",
      "sponsor_name": "Y-MABS THERAPEUTICS INC",
      "openfda": {
        "application_number": [
          "BLA761171"
        ],
        "brand_name": [
          "DANYELZA"
        ],
        "generic_name": [
          "NAXITAMAB"
        ],
        "manufacturer_name": [
          "BTG International Inc.",
          "Y-mAbs Therapeutics, Inc."
        ],
        "product_ndc": [
          "50633-230",
          "73042-201"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "INTRAVENOUS"
        ],
        "substance_name": [
          "NAXITAMAB"
        ],
        "rxcui": [
          "2474239",
          "2474244"
        ],
        "spl_id": [
          "52bb5505-85d0-256a-e063-6294a90a73a8",
          "75b08b15-496c-4b4c-bf71-f0220b0d58b3"
        ],
        "spl_set_id": [
          "b0f5ee96-369f-4cb9-a783-3bfa70fe8f90",
          "29a80c6b-8bad-4650-8c7f-f18490c868ec"
        ],
        "package_ndc": [
          "50633-230-01",
          "73042-201-01"
        ],
        "nui": [
          "N0000191500",
          "N0000191499"
        ],
        "pharm_class_epc": [
          "Glycolipid Disialoganglioside-directed Antibody [EPC]"
        ],
        "pharm_class_moa": [
          "Glycolipid Disialoganglioside-directed Antibody Interactions [MoA]"
        ],
        "unii": [
          "9K8GNJ2874"
        ]
      },
      "products": [
        {
          "product_number": "001",
          "reference_drug": "No",
          "brand_name": "DANYELZA",
          "active_ingredients": [
            {
              "name": "NAXITAMAB-GQGK",
              "strength": "40MG/10ML"
            }
          ],
          "reference_standard": "No",
          "dosage_form": "SOLUTION",
          "route": "INTRAVENOUS",
          "marketing_status": "Prescription"
        }
      ]
    }
  ]
}